SLS | tickerfilter.com

Fundamental analysis

Profitability 8%

Dept financing 13%

Liquidity 38%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.22%

1 Month

9.22%

3 Months

-23.80%

6 Months

-12.61%

1 Year

82.72%

2 Year

-66.46%

Key data

Stock price

$0.91

P/E Ratio

0.00

DAY RANGE

$0.90 - $0.93

EPS

-$2.13

52 WEEK RANGE

$0.52 - $1.72

52 WEEK CHANGE

$82.72

MARKET CAP

80.416 M

YIELD

N/A

SHARES OUTSTANDING

64.332 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,734,465

AVERAGE 30 VOLUME

$1,354,405

Company detail

CEO: Angelos M. Stergiou
Region: US
Website: sellaslifesciences.com
Employees: 10
IPO year: 2008

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

SELLAS Life Sciences Group, Inc. focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapy that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials. The company was founded in 2012 and is headquartered in New York, New York.

SLS - SELLAS Life Sciences Group, Inc.